Keywords: Lpath, Merck KGaA Asonep, Solid tumors, Partners
Lpath gets $2 million milestone form Merck KGaA on completing Asonep Ph I study, but rejects opt-in extension
Article | 31 March 2010
California, USA-based lipidomics-based therapeutics Lpath has announced positive summary results of its dose-escalation Phase I clinical trial of the investigational ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
